Skyhawk Therapeutics (Group)

https://www.skyhawktx.com

Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTAR™ (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients. *

	Start	2019-01-04 existent
	Industry	small-molecule drug
	Industry 2	SkySTAR™ technology platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA)
	Person	Haney, Bill (Skyhawk Therapeutics 201901 CEO + Co-Founder)

	Region	Waltham, MA
	Country	United States (USA)
	Street	35 Gatehouse Drive
	City	02451 Waltham, MA
	Tel	+1-617-858-0041
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Biogen Inc.. (1/4/19). "Press Release: Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets". Cambridge, MA & Waltham, MA.

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Skyhawk Therapeutics (Group)

[1] Biogen Inc.. (1/4/19). "Press Release: Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets". Cambridge, MA & Waltham, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]